GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior

The induction of nausea and emesis is a major barrier to maximizing the weight loss profile of obesity medications, and therefore, identifying mechanisms that improve tolerability could result in added therapeutic benefit. The development of peptide YY (PYY)-based approaches to treat obesity are no...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 71; no. 7; pp. 1410 - 1423
Main Authors Samms, Ricardo J., Cosgrove, Richard, Snider, Brandy M., Furber, Ellen C., Droz, Brian A., Briere, Daniel A., Dunbar, James, Dogra, Mridula, Alsina-Fernandez, Jorge, Borner, Tito, De Jonghe, Bart C., Hayes, Matthew R., Coskun, Tamer, Sloop, Kyle W., Emmerson, Paul J., Ai, Minrong
Format Journal Article
LanguageEnglish
Published United States American Diabetes Association 01.07.2022
Subjects
Online AccessGet full text
ISSN0012-1797
1939-327X
1939-327X
DOI10.2337/db21-0848

Cover

Loading…